Mira Pharmaceuticals Inc (MIRA)
0.738
+0.03
(+3.93%)
USD |
NASDAQ |
Jun 14, 16:00
0.71
-0.03
(-3.79%)
Pre-Market: 08:41
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.91M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.456 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. |
| URL | https://www.mirapharmaceuticals.com |
| Investor Relations URL | https://www.mirapharmaceuticals.com/investors |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Sep. 13, 2024 (est.) |
| Last Earnings Release | May. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. |
| URL | https://www.mirapharmaceuticals.com |
| Investor Relations URL | https://www.mirapharmaceuticals.com/investors |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Sep. 13, 2024 (est.) |
| Last Earnings Release | May. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |